(Business Wire)  Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer will present a corporate update at the 22^nd Annual Future Leaders in the Biotech Industry Conference on Friday, March 20, 2015 at 2:30 p.m. ET in New York.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals is inspired to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. Our small-molecule drugs are specifically engineered to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera’s unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera’s business strategy is to advance its drug candidates for genetically-defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.

Deciphera’s internal product pipeline includes altiratinib a MET/TIE2/VEGFR2/TRK kinase inhibitor currently in Phase 1 clinical development, a pan-KIT inhibitor (DCC-2618) currently in preclinical development and rebastinib, a TIE2/VEGFR1 kinase inhibitor currently in Phase 1 clinical development. Partnered programs include a pan-RAF inhibitor (LY-3009120) developed in collaboration with Eli Lilly. Additional research-stage programs are also in development.